Anticoagulant News and Research

RSS

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

First study to elucidate how statins reduce activation of abnormal blood clotting

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.

5 Jan 2012

ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.

23 Dec 2011

Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE

ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. The trial has recruited patients from 36 centers across Europe.

17 Dec 2011

Study evaluates use of leukocyte and platelet-rich fibrin biomaterial in heart patients

Cardiac patients that take anticoagulant medications and need a tooth extraction face an increased risk of bleeding that must be addressed by the treating clinician. Therefore, a protocol for heart patients is needed that will avoid significant bleeding after dental extractions without suspending anticoagulant therapy.

15 Dec 2011

Study finds underutilization of warfarin among Kentucky women with AF

Dr. Rabab Mohsin, an internal medicine resident at the University of Kentucky, working with Dr. Alison Bailey of the University of Kentucky Gill Heart Institute, has discovered that the drug warfarin was underutilized in a large study group of women.

14 Dec 2011

ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.

13 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

New method improves accuracy of AF risk assessments

Elderly people with atrial fibrillation are often treated with anticoagulants to thin the blood, but this medicine is hard to dose and patients have to have their blood tested regularly. Researchers at the Sahlgrenska Academy at the University of Gothenburg and Chalmers University of Technology have now devised a new method that improves the accuracy of risk assessments.

7 Dec 2011

Researchers discover new tick-borne infection

Researchers at the University of Gothenburg's Sahlgrenska Academy have discovered a brand new tick-borne infection. Since the discovery, eight cases have been described around the world, three of them in the Gothenburg area, Sweden.

7 Dec 2011

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

Xeltis, a biomedical technology company developing growing, living and self-healing cardiovascular implants using tissue-engineering technology, has announced conditional approval by the Paul Erlich Institute (PEI) in Germany to commence the first clinical study of its tissue-engineered cardiovascular grafts.

6 Dec 2011

The Lipitor story: Drug companies brace for losses as patents expire on this and other popular medications

News outlets analyze the impact that generic Lipitor could have on costs and the "era of 'blockbuster drugs'" as well as the strategies from Lipitor's maker to block its generic competitors. Meanwhile, some of these generics are already reaching the marketplace.

2 Dec 2011

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

29 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Drug-coated balloon restores blood flow in narrowed bare metal stent

A drug-coated balloon inserted in a narrowed bare metal stent is a promising therapy for restoring blood flow, according to research presented at the American Heart Association's Scientific Sessions 2011.

17 Nov 2011

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Researchers announce new method to build important heparin drug

Robert Linhardt is working to forever change the way some of the most widely used drugs in the world are manufactured. Today, in the journal Science, he and his partner in the research, Jian Liu, have announced an important step toward making this a reality. The discovery appears in the October 28, 2011 edition of the journal Science in a paper titled "chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparins."

28 Oct 2011

Enoxaparin can reduce risk of VTE in plastic surgery patients

For plastic surgery patients at high risk, treatment with the anticoagulant (blood-thinning) drug enoxaparin can reduce the risk of serious blood clot-related complications called venous thromboembolism (VTE), reports a study in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

28 Oct 2011

New book on pediatric stroke and cerebrovascular diseases

Two decades after the first edition, a third edition of the definitive textbook on stroke in children -- Pediatric Stroke and Cerebrovascular Disorders -- has been published by Demos Medical Publishing of New York City.

15 Oct 2011